Study Title | A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab GM-CSF Irinotecan and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C) |
---|---|
Protocol ID | I3Y-MC-JPCS |
Disease (Sub Disease) | Solid Tumours |
Diagnosis Stage | Relapsed/refractory |
Location | QLD / VIC / WA |
Sponsor | Eli Lilly and Company |
Links | https://clinicaltrials.gov/ct2/show/NCT04238819 |
Trial Status | Closed to Recruitment |
Trial Open Date | 09/11/2020 |
Sites | Perth Children's Hospital/ Royal Children's Hospital / Queensland Children's Hospital |
Study Type | Treatment |
Phase | Phase 1/2 |
Age Eligibility | up to 21 Years |
International registry ID's | NCT04238819 |